The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)


Balancing risks and benefits of left main revascularisation strategies in patients with chronic kidney disease

EuroIntervention 2020;16:13-15. DOI: 10.4244/EIJV16I1A1

1. The Zena and Michael A. Wiener Cardiovascular Institute, The Icahn School of Medicine at Mount Sinai, New York, NY, USA; 2. Cardiovascular Research Foundation, New York, NY, USA

Coronary artery disease (CAD) is the leading cause of death in patients with chronic kidney disease (CKD)1. Patients with CKD and CAD undergoing percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) have a poor prognosis1,2. In fact, CKD attenuates the benefits of myocardial revascularisation due to the higher risk of procedural complications, reduced durability of both surgical and percutaneous revascularisation techniques and the high risk of death from non-cardiac causes1. Historically, patients with CKD have been excluded from randomised controlled trials evaluating management strategies for CAD, particularly those with advanced CKD1. Recently, in the ISCHEMIA-CKD trial, patients ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Read next article
Predicting the future for left main revascularisation. Choosing the right fortune teller…